Vertex Pharmaceuticals Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
6,400
- Stock Symbol
-
VRTX
- Investments
-
22
- Share Price
-
$538.60
- (As of Friday Closing)
Vertex Pharmaceuticals General Information
Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Contact Information
Website
www.vrtx.comCorporate Office
- 50 Northern Avenue
- Boston, MA 02210
- United States
Corporate Office
- 50 Northern Avenue
- Boston, MA 02210
- United States
Vertex Pharmaceuticals Stock Performance
As of 13-Nov-2026, Vertex Pharmaceuticals’s stock price is $538.60. Its current market cap is $137B with 254M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $538.60 | $542.62 | $412.27 - $568.67 | $137B | 254M | 1.24M | $15.67 |
Vertex Pharmaceuticals Financials Summary
As of 30-Sep-2026, Vertex Pharmaceuticals has a trailing 12-month revenue of $13B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 126,637,106 | 110,573,769 | 98,885,445 | 93,665,211 |
| Revenue | 12,951,600 | 12,001,300 | 11,020,100 | 9,869,200 |
| EBITDA | 4,560,000 | 4,375,400 | (111,800) | 3,990,500 |
| Net Income | 3,975,900 | 3,953,200 | (535,600) | 3,619,600 |
| Total Assets | 32,736,300 | 25,643,000 | 22,533,200 | 22,730,200 |
| Total Debt | 6,478,400 | 2,030,500 | 1,744,300 | 808,400 |
Vertex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vertex Pharmaceuticals Comparisons
Industry
Financing
Details
Vertex Pharmaceuticals Competitors (47)
One of Vertex Pharmaceuticals’s 47 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Vertex Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vertex Pharmaceuticals Patents
Vertex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236179-A1 | Spcas9 hnh domain deletion for an improved rt editor | Pending | 06-May-2025 | ||
| WO-2026226539-A1 | Electrospun membranes for macroencapsulation devices | Pending | 22-Apr-2025 | ||
| WO-2026226535-A1 | Macroencapsulation devices including membrane openings | Pending | 22-Apr-2025 | ||
| WO-2026213321-A1 | Phd inhibitors and uses thereof | Pending | 02-Apr-2025 | ||
| WO-2026213192-A1 | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator | Pending | 01-Apr-2025 | A61K9/146 |
Vertex Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vertex Pharmaceuticals Investments & Acquisitions (22)
Vertex Pharmaceuticals’s most recent deal was a Merger/Acquisition with Crinetics Pharmaceuticals for . The deal was made on 01-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | 01-Sep-2026 | Merger/Acquisition | Drug Discovery | ||
| Arbor Biotechnologies | 30-Oct-2025 | Later Stage VC | Drug Discovery | ||
| Septerna (Novel G Protein-Coupled Receptor Program) | 12-Sep-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Alpine Immune Sciences | 20-May-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Entrada Therapeutics | 08-Feb-2023 | PIPE | Drug Delivery |
Vertex Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.29 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vertex Pharmaceuticals Exits (6)
Vertex Pharmaceuticals’s most recent exit was on 09-Sep-2021 from Obsidian Therapeutics. The exit was categorized as with 17 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Obsidian Therapeutics | 09-Sep-2021 | Completed |
|
||
| Kymera Therapeutics | 11-Mar-2020 | Completed |
|
||
| Kymera Therapeutics | 15-May-2019 | Completed |
|
||
| Moderna | 07-Sep-2016 | Completed |
|
||
| CRISPR Therapeutics | 24-Jun-2016 | Early Stage VC | Completed |
|
Vertex Pharmaceuticals Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Torreyana Insurance Company | Burlington, VT | 2018 | |
| Vertex Pharmaceuticals (canada) Incorporated | Toronto, Canada | 2013 | |
| Crinetics Pharmaceuticals | San Diego, CA | 2008 |
Vertex Pharmaceuticals FAQs
-
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989.
-
Where is Vertex Pharmaceuticals headquartered?
Vertex Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Vertex Pharmaceuticals?
Vertex Pharmaceuticals has 6,400 total employees.
-
What industry is Vertex Pharmaceuticals in?
Vertex Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Vertex Pharmaceuticals a private or public company?
Vertex Pharmaceuticals is a Public company.
-
What is Vertex Pharmaceuticals’s stock symbol?
The ticker symbol for Vertex Pharmaceuticals is VRTX.
-
What is the current stock price of Vertex Pharmaceuticals?
As of 13-Nov-2026 the stock price of Vertex Pharmaceuticals is $538.60.
-
What is the current market cap of Vertex Pharmaceuticals?
The current market capitalization of Vertex Pharmaceuticals is $137B.
-
What is Vertex Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Vertex Pharmaceuticals is $13B.
-
Who are Vertex Pharmaceuticals’s competitors?
Regeneron Pharmaceuticals, Genetix Biotherapeutics, Ionis Pharmaceuticals, Altimmune, and Inovio Pharmaceuticals are some of the 47 competitors of Vertex Pharmaceuticals.
-
What is Vertex Pharmaceuticals’s annual earnings per share (EPS)?
Vertex Pharmaceuticals’s EPS for 12 months was $15.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
